EUCTR2015-004110-23-DK进行中（未招募）1 期
An Open-Label, Multicenter Study to Evaluate the Long-term Safety of Weekly Intravenous Alphal-Proteinase Inhibitor (Human), ModifiedProcess 60 mg/kg in Subjects With Pulmonary Emphysema Due to Alpha1-Antitrypsin Deficiency - SPARTA-OLE
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 250
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •a. Has completed participation in Study GTi1201 (ie, completed Week 156 and Week 160/End-of-Study Visit)
- •b. Has experienced a decline in FEV1 at the annualized rate of =134.4 mL/year at or after the Week 104 Visit in GTi1201.
- •2. Is willing and able to provide informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 220
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 30
排除标准
- •1. Is unable to physically or mentally undergo a CT scan (eg, unable to fit inside the CT scanner, claustrophobic).
- •2. Has severe concomitant disease including, but not limited to, congestive heart failure and liver cirrhosis.
- •3. Has primary and/or secondary (metastatic disease) pulmonary malignancy or other current malignancy with <1 year predicted overall survival.
- •4. Has a metal object (newly received since starting GTi1201) that might interfere with chest CT quality and quantification. Metal objects include, but are not limited to, cardiac pacemaker, defibrillator, metal prosthetic heart valve, metal projectile, metal weapon fragments, or metal shoulder prosthesis.
- •5. Is a female who is pregnant, breastfeeding or, if of child-bearing potential, unwilling to practice a highly effective method of contraception (oral, injectable, or implanted hormonal methods of contraception; placement of an intrauterine device or intrauterine system; condom or occlusive cap with spermicidal foam/gel/film/cream/suppository; male sterilization; or abstinence) throughout the study.
- •6. Has clinical signs and symptoms of viral infection requiring virus safety testing at the Week 160/End-of-Study Visit or Early Discontinuation Visit in Study GTi1201, and the virus safety test results are indicative of acute or chronic infection with hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), or parvovirus B19 (B19V). Note: If the virus safety test results are indicative of acute or chronic infection with HAV, HBV, HCV, HIV, or B19V, the subject will be considered a screen failure and must be withdrawn from the study.
- •7. Has current evidence of smoking, which includes electronic/vapor cigarettes, or has a positive urine cotinine test at the Week 160/End-of-Study Visit in Study GTi1201 that is due to smoking.
- •8. Has current evidence of chronic alcoholism or illicit drug abuse (addiction).
- •9. Is currently participating in another investigational product (IP) study.
- •10. Has a history of anaphylaxis or severe systemic response to any plasma-derived alpha1-PI preparation or other blood product(s).
- •11. In the opinion of the investigator, is likely to have compliance problems with the protocol and the procedures of the protocol.
- •12. Has any medical condition that the investigator feels might confound the results of the study or pose an additional risk to the subject during study participation.
研究者
相似试验
进行中（未招募）
1 期
A Study with an active treatment to Assess the Long-term Safety of Weekly Intravenous Product in Subjects with Pulmonary Emphysema due to Alpha1-Antitrypsin DeficiencyEUCTR2015-004110-23-FIGrifols Therapeutics LLC250
进行中（未招募）
1 期
A Study with an active treatment to Assess the Long-term Safety of Weekly Intravenous Product in Subjects with Pulmonary Emphysema due to Alpha1-Antitrypsin DeficiencyPulmonary Emphysema due to Alpha-1-Antitrypsin DeficiencyMedDRA version: 20.0Level: LLTClassification code 10014563Term: Emphysema pulmonarySystem Organ Class: 100000004855EUCTR2015-004110-23-PLGrifols Therapeutics LLC250
进行中（未招募）
1 期
An Open-label, Multicenter Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of AEB1102 in Patients with Arginase I DeficiencyEUCTR2018-003163-67-PTAeglea Biotherapeutics, Inc.14
进行中（未招募）
1 期
An Open-label, Multicenter Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of AEB1102 in Patients with Arginase I DeficiencyArginase 1 deficiency HyperargininemiaMedDRA version: 20.0 Level: PT Classification code 10062695 Term: Arginase deficiency System Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2018-003163-67-GBAeglea Biotherapeutics, Inc.14
进行中（未招募）
不适用
An Open Label, Multicenter Study to Evaluate the Long Term Safety of Prolonged Release (PR) OROS Methylphenidate (18, 36, 54, 72 and 90 mg/day) in Adults with Attention Deficit/Hyperactivity DisorderEUCTR2005-004037-18-PTJanssen-Cilag EMEA400